Organizing Committee

Prof. James E. Trosko,

Prof. James E. Trosko,

Ph.D., Professor Emeritus Center for Integrative Toxicology, College of Human Medicine, Michigan State University, USA

After receiving a Ph.D. in radiation genetics, Dr. Trosko did a postdoctoral fellowship at Oak Ridge National Laboratory (1963-66) in DNA damage/repair and in vitro mutagenesis. He published the first paper showing that normal human cells could repair their UV-damaged DNA. He went to Michigan State University (1966) to work on the xeroderma pigmentosum. Later, after receiving a NCI-Career Development award, he went to work at the McArdle Laboratory for Cancer Research-University of Wisconsin on chemical carcinogenesis. After returning to MSU, Trosko’s lab developed 4 new in vitro assays to detect non-genotoxic chemicals that had teratogenic, tumor promoting, immuno-modulatory, neuro-, cardiovascular -and reproductive- toxic effects. He was featured on the cover of Cancer Research as one of the investigators who linked gap junctions to the carcinogenesis process. He coined the term, “epigenetic toxicology”, his lab discovered that oncogenes, such as src, ras, raf, neu could stably inhibit GJIC, while tumor suppressor genes, as well as multiple cancer chemo-preventive agents (green tea components, caffeic acid ethyl ester, genistein, beta-sitosterol, resveratrol, retinoids, carotinoids, kaempherol, etc.), and even some chemotherapeutic agents (Lovastatin, SAHA).
All this was done based on assuming the “stem cell theory of cancer”. That led his lab to search for the few stem cells that must exist in normal tissues of cancer-generating organs. Together with Dr. Chia- Cheng Chang, they discovered, in 1986, a human adult stem cell from the kidney. It was based on assuming stem cells had no functional gap junctions. Later, they discovered human breast epithelial stem cells, and other adult stem cells (pancreas, mesenchyme, liver). This led Dr. Trosko to hypothesize that the adult stem cell was the target for breast (and other cancers) and he successfully demonstrated this in his paper showing the adult human breast stem cell could be immortalized and subsequently neoplastically transformed.  In 1990-92, Dr. Trosko was Chief of Research at the Radiation Effects Research Foundation (RERF) in Hiroshima, Japan. After returning to MSU, he demonstrated that Oct4A was a biomarker for human adult stem cells and that the human adult breast stem cell was the target cell for breast neoplastic transformation and the probable origin of the human breast “cancer stem cell”. He spent a sabbatical studying human prostate stem cells and the Mediterranean diet at ARNAS-Civic Cancer Institute, Palermo, Sicily and 6 months at Seoul National University in the Human Adult Stem Cell Laboratory, where he is continuing his studies on characterizing adult human stem cells for their potential uses in drug discovery & toxicity assessment. He has been recognized as a model teacher [ one specific example is his first graduate student’s achievement, Dr. Stephen Warren, discover of the cloned Fragile X gene] and an internationally-recognized basic science cancer researcher , in the fact that Dr. Trosko has given over 700 lectures around the world .and research mentor by awards such as the MSU-Teacher Scholar; MSU Distinguished Professor; NCI- Career Development Awardee; Sigma Xi Senior Research Scholar; Japan Society for the Promotion of Science; Korean Ministry of Science & Technology’s “Brain Pool” Awardee; and Seoul National University “World Class University Invited Professorship”

Prof. Mariusz Z. Ratajczak

Prof. Mariusz Z. Ratajczak

Director - Stem Cell Institute, Division of Hematology/Oncology,, James Graham Brown Cancer Center, University of Louisville, USA

Mariusz Z. Ratajczak, M.D., PhD, D.Sci d.hc is the Henry and Stella Hoenig Endowed Chair in Cancer Biology and the Director of the Developmental Biology Research Program at the University of Louisville's James Graham Brown Cancer Center and Head of Department of Regenerative Medicine, Warsaw Medical University, Poland. Dr. Ratajczak earned his M.D. at the Pomeranian Medical University and his Ph.D. and D.Sci at the Polish Academy of Sciences in Warsaw, Poland and completed fellowships at the Polish Academy of Sciences and the University of Pennsylvania in Philadelphia. He is an internationally known investigator in the field of adult stem cell biology.  His 2005 discovery of embryonic-like stem cells in adult tissues has the potential to revolutionize the field of regenerative medicine. This discovery provides an avenue to guide the development of new treatments for cancer, heart disease, eye disease, diabetes and neurodegenerative disorders.

Dr. Ratajczak is an internationally known specialist in the field of adult stem cell biology.  His 2005 discovery of embryonic-like stem cells in adult bone marrow tissues has the potential to revolutionize the field of regenerative medicine. This discovery may lead to new treatments for cancer, heart disease, eye disease, diabetes and neurodegenerative disorders. Dr. Ratajczak is also known from his work on novel mechanisms of mobilization and homing of stem cells, biological role of extracellular microvesicles and molecular mechanisms of cancer metastasis.

Dr. Brij M. Gandhi

Dr. Brij M. Gandhi

CEO & founder of Neo BioMed Services, Former Adviser, Dept. of Biotechnology, Ministry of Science & Technology, Government of India

 

Dr. Brij. M. Gandhi, M.Sc.(Biochemistry) and Ph.D. (Experimental Medicine, Norway) is presently CEO and founder of Neo BioMed Services (www.neobiomed.com), providing services and consultancy in health areas and regulatory issues related to biopharmaceuticals, pharmaceuticals, including stem cell and regenerative medicine. As Adviser to the Government of India, Dr. Gandhi was involved in management, promotion and policy issues in biotechnology related to international collaborations, medical biotechnology including stem cells and regenerative medicine, infrastructure development, animals and aquaculture biotechnology, biosafety and biosecurity. Prior to that he was Research Scientist at AIIMS, New Delhi working on immunology of parasitic, bacterial and viral infections including amoebic diseases; hepatitis; liver diseases; IVD; food and nutritional health issues.

Dr. Gandhi was trained at MIT, USA; LSHTM, London, NIH, USA, Hvidovre Hospital, Copenhagen and University of Bergan, Norway. Dr. Gandhi continues to serve as Advisor / Director to a number of institutions/pharma and biopharma industries with an experience of about 50 years as research scientist, science manager, adviser/consultant and having over 155 publications. 

 

Dr. Joel I. Osorio

Dr. Joel I. Osorio

Sole Founder & President, RegenerAge Medical Biotechnology, Regenerative & Translational Medicine Initiative, USA

Dr. Osorio is an innovative businessman with a distinct entrepreneurial mindset concentrated in adding value on the areas of Biotechnology (mRNA), Reprogramming & Regenerative Medicine for translational use in humans and a variety of clinical applications aimed for both the private and the public health sectors. He is the CEO of RegenerAge Clinic and RegenerAge Beauty. VP and Clinical Developer for Bioquark,Inc. CCO at Reanima Advance Biosciences Project. President at Dr. Jois® an anti-aging, beauty and cosmetic products endorsement company. VP and Chairman of the WAMS Americas Division. Earned MD degree at Westhill University. Diplomate in aesthetic medicine (UAG), Advance Fellow by the ABAARM, visiting scholar at UNC at Chapel Hill in Dermatology. Fellow in Stem Cell Medicine by the A4M and USF, Business Diplomate at ECA, enrolled Master on Health Sciences at Victoria University.

 

Has appeared on several occasions on International media, some of his latest broadcast appearances are CNN español, TV Azteca, Excelsior Newspaper, Medicable, PharmaBoard Room, and Podcasts among others.His public appearances as a speaker at the 27th A4M Spring Congress 2019 (Orlando), the 2018 RAADfest (San Diego), 3rd International Conference on Molecular Medicine and Diagnostics (Dubai), Global Academic Business Forum on Tissue Engineering and Regenerative Medicine (Baltimore), Second International Congress on mHealth (Shiraz), 6th International Conference on Tissue Engineering and Regenerative Medicine (SFO), 11th World Congress on Cell & Tissue Science (Tokyo), 17th International Conference on Neurology and Neuroscience (Toronto), 9th International Conference & Exhibition on Tissue Science and Regenerative Medicine (Las Vegas) among others, makes him a pioneer on the Regenerative + Reprogramming Medicine Field.

 

Prof. Ke Cheng

Prof. Ke Cheng

Ph.D, Professor, Regenerative Medicine, NC State University, USA

Ke Cheng is Professor in the Department of Molecular Biomedical Sciences at the College of Veterinary Medicine and Professor in the UNC/NCSU joint Department of Biomedical Engineering. He is also an adjunct professor at the UNC Eshelman School of Pharmacy and UNC School of Medicine. He directs the Bio Therapeutics Lab which focuses on stem cells, biomaterials, and Nano medicine for heart and lung regeneration. His lab also studies novel mechanisms of cell extravasation, termed angiopellosis.Prior to this position, Ke was an Assistant Professor at Cedars-Sinai Medical Center and University of California Los Angeles School of Medicine, where his research focused on stem cells and regenerative medicine in animal models. Ke also served as the director of the stem cell lab for multiple clinical trials including a clinical trial using patient's own cardiac stem cells to treat heart attack. Ke's formal education began with a B.S. in Pharmaceutical Engineering from the Zhejiang University, followed by a Ph.D. degree in Biological Engineering from University of Georgia.
Research Area:  Regenerative Medicine, Stem Cell Theory
Research Interests:  Biomaterials, Nano medicines, and stem cells for cardiovascular and pulmonary regeneration; Exosomes and micro-RNAs, regenerative medicine.

Dr. Nadia Benkirane-Jessel

Dr. Nadia Benkirane-Jessel

PhD, Research Director, Head of “Regenerative Nano Medicine”, INSERM, France

 Dr. Nadia Benkirane is Research director (DR1) at INSERM (French National Institute for Health and Medical Research) and head of the “Regenerative Nano medicine” laboratory, UMR 1260 Inserm-Unistra, Strasbourg, France. She was leader of “Active Biomaterials and Tissue Engineering” team INSERM 977. She received her Ph.D. from University Louis Pasteur, ULP, Strasbourg, France for the work on Development of pseudo peptides as synthetic vaccines. Dr. Jessel (Benkirane) then held a postdoctoral position in collaboration with the Institute Pasteur, Paris, France, working on Immunotherapy HIV, and another postdoctoral position on the application of modified peptides as vaccines against FMDV (Plum Island Animal Disease Center, ARS, USDA, Greenport, NY 11944-0848, USA). She joined the INSERM U595 in 2002 as a post-doc, and received the diploma to direct the research (HDR) in 2004. Dr. Jessel got the permanent position (CR1) in the INSERM 595 laboratory in 2004 and Research Director (DR2) position in the INSERM 977 and head of “active Biomaterials and Tissue Engineering team from 2009 until 2012). Currently Research Director (DR1) and head of the INSERM UMR 1260 (Regenerative Nano medicine “. Dr. Jessel possesses expertise in diverse fields of molecular and cellular biology, immunochemistry, tissue engineering and biomedical engineering. In the last 10 years, she focused her research on the bio-functionalization of multilayered polyelectrolyte architectures with emphasis on the use of these architectures to induce specific cellular responses and gain control over cell proliferation and differentiation. Dr. BENKIRANE-JESSEL has more than 138 publications (h index: 36) with peer-reviewed publications in high impact factor journals (Proc. Nat. Acad. Sci. USA; Adv. Mater.; Adv. Funct. Mater.; Small; Nano letters, Biomaterials, ACS Nano), 5 chapters’ reviews and 5 international patents, she is a regular referee for a number of scientific journals (Nature nanotechnology, Nature Materials, ACS Nano, Biomaterials, Nano letters…). She was under the contract (Interface INSERM/Clinic 2008-2013) and she got also “Prime d ‘Excellence Scientifique” from the INSERM, 2010-2014 and the PEDR from the INSERM on 2016 for 4 years.